Addendum

Guselkumab (plaque psoriasis) - Addendum to Commission A17-60

Status
Status: Commission completed
Project no.
A18-24
Last updated

Report documents

  1. Addendum

    Guselkumab (plaque psoriasis) - Addendum to Commission A17-60

    published on
    Document type
    PDF document, 544 kB, EN, not accessible

Dossier assessment

Indication:

Adults with moderate to severe plaque psoriasis with inadequate response to other systemic treatments or with contraindication or intolerance

Result of dossier assessment:

Based on the study data subsequently submitted, there is now proof of a major added benefit in this therapeutic indication

Additional information

Federal Joint Committee (G-BA)

2018-05-17 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A18-24
Commission
Commission awarded on 09.04.2018 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-60
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form